Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5352W HIGH $7.55
Volume
616.01 K
Value Traded
4.51 M
Short % Float
3.05%
+0.41%Week
-1.75%1 Month
+20.9%3 Month
+19.51%6 Month
-86.6%5 Year
-96.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
53.86 M
EPS (TTM)
-6.18
P/E Ratio
-
Ent. Value
-11.02 M
Total Shares
7.33 M
Float Shares
5.20 M
Insiders
17.37%
Institutions
60.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
KZR Catalyst Timeline
Dated clinical, regulatory and corporate events for Kezar Life Sciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How KZR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | Zetomipzomib | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Kezar Life Sciences, Inc. faces pipeline headwinds (25/100), with $55M risk-adjusted pipeline value, led by zetomipzomib in Autoimmune Hepatitis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| zetomipzomib Small moleculeCompletedNCT05569759 | Autoimmune Hepatitis | Phase 2 | COMPLETED | 24 | Apr 30, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every KZR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Zetomipzomib | Autoimmune Hepatitis (AIH) | Phase 2a | 2025-03-25 | 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg day or less, compared to 0 of 7 of placebo patients; 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper ( 5 mg day), compared to 1 of 8 placebo patients; Median duration of response in zetomipzomib patients achieving a CR was 27.6 weeksRead More | Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 FiRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wallace CourtneyDirector | Disposition | -3,500 | $0.00 | 05/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KZR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.3 % (50 %) | 4.93 M | 664.31 K |
KZR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KZR ranks across every disease it competes in
Competitive Position is a premium feature
See how KZR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKZR News
About Kezar Life Sciences, Inc.
Headquarters4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next KZR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime